In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris

Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of Candida auris and Other Candida Species

(2017) Christina T. Piedrahita et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast Candida auris on a Plastic Health Care Surface

(2017) Rory M. Welsh et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Current perspective on emergence, diagnosis and drug resistance in Candida auris

(2017) Smita Sarma et al.   Infection and Drug Resistance

Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability

(2017) Michael R Hodges et al.   Open Forum Infectious Diseases

Simultaneous Emergence of Multidrug-ResistantCandida aurison 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses

(2016) Shawn R. Lockhart et al.   CLINICAL INFECTIOUS DISEASES

Investigation of the First Seven Reported Cases ofCandida auris,a Globally Emerging Invasive, Multidrug-Resistant Fungus — United States, May 2013–August 2016

(2016) Snigdha Vallabhaneni et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

From the blood to the brain: avenues of eukaryotic pathogen dissemination to the central nervous system

(2015) Norikiyo Ueno et al.   CURRENT OPINION IN MICROBIOLOGY

The Investigational Agent E1210 Is Effective in Treatment of Experimental Invasive Candidiasis Caused by Resistant Candida albicans

(2014) Nathan P. Wiederhold et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Inhibiting GPI Anchor Biosynthesis in Fungi Stresses the Endoplasmic Reticulum and Enhances Immunogenicity

(2012) Catherine A. McLellan et al.   ACS Chemical Biology

In VitroActivity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods

(2011) Michael A. Pfaller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds

(2011) Mamiko Miyazaki et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

E1210, a New Broad-Spectrum Antifungal, Suppresses Candida albicans Hyphal Growth through Inhibition of Glycosylphosphatidylinositol Biosynthesis

(2011) Nao-aki Watanabe et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods

(2011) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method

(2011) Michael A. Pfaller et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods

(2011) M. A. Pfaller et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Echinocandin Antifungal Drugs in Fungal Infections

(2010) Sharon C.-A. Chen et al.   DRUGS

Candida aurissp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital

(2009) Kazuo Satoh et al.   MICROBIOLOGY AND IMMUNOLOGY